메디포스트

078160KOSDAQ

43.5 / 100

Reference Date: 2026-10-23

Financial Score14.0 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 1.6% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Medipost operates three main business segments: umbilical cord blood banking, stem cell therapeutics (Cartistem), and health functional foods. In 2024, the company achieved a record sales revenue of 70.7 billion won, driven by strong performance in its cord blood banking division, which holds the top market share domestically, and its stem cell therapeutics division expanding global clinical trials.

Number of Employees

684people

Average Salary

61.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.34Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

-34.23Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

33.95Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲3.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼66.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 8,530Won52-week high 28,00052-week low 7,520

1-month return3.0Point

1m -1.61% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주주총회소집공고2026-10-14
Neutral의결권대리행사권유참고서류2026-10-14